Last reviewed · How we verify
Oslif
Oslif, marketed by Fundacio Privada Mon Clinic Barcelona, is a drug with a key composition patent expiring in 2028. The primary strength of Oslif lies in its current market presence, leveraging the patent protection to maintain exclusivity. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Oslif |
|---|---|
| Also known as | LABA |
| Sponsor | Fundacio Privada Mon Clinic Barcelona |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- ANTES B+ Clinical Trial (PHASE4)
- Preference Tiotropium Respimat Study in COPD
- Closing Volume Interpretation and Bronchodilators Effect (PHASE4)
- Effect of Indacaterol Maleate in Chronic Obstructive Pulmonary Disease (COPD) on Lung Volume and Related Dyspnea (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oslif CI brief — competitive landscape report
- Oslif updates RSS · CI watch RSS
- Fundacio Privada Mon Clinic Barcelona portfolio CI